Definitive Contract HT942524C0049
Award Date
9/20/24
Potential Completion Date
9/19/26
Potential Value
$2.3M
Federal Agency
Defense Health Agency
Awardee
Synedgen, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Claremont, CA 91711, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase III Action
Primary Consortia Member
Not listed
Similar Awards
The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) awarded a $119,642,445 Cost Plus Fixed Fee contract to Synedgen, Inc., a for-profit organization, to advance the development of PAAG17G (drug product: MIIST305), a once-daily, orally administered, gut-restricted drug to reduce mortality and morbidity arising from acute exposure to ionizing radiation, specifically gastrointestinal (GI) injury (GI-AR). This contract was not set aside...
This is a firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Zymeron Corporation, a Minority Owned Small Business, under the Small Business Innovation Research (SBIR) program. The $249,991.85 Phase I award supports research and development of "Prophylactics for Ionizing Radiation-Induced Hematopoietic Subsyndrome of Acute Radiation Syndrome (ARS)". The contract has a completion date of July 23, 2021. Zymeron is a research-based biotechnology company that...
This is a Firm Fixed Price (FFP) contract awarded by the U.S. Army Medical Command (MEDCOM) to Technology Holding LLC, a small business, for a Small Business Innovation Research (SBIR) Phase II project titled "Novel Biologic Countermeasure for Acute Radiation Syndrome." The contract has a ceiling value of $2,999,993.84 and a period of performance from June 2022 to October 2025. The R&D effort is focused on developing a novel biologic countermeasure to address acute radiation...
This is a Department of the Army Medical Command Small Business Innovation Research (SBIR) Phase I contract awarded to Technology Holding LLC, a for-profit limited liability company focused on research and development across biotechnology, materials science, energy, and defense. The $249,970.74 firm-fixed-price contract is for a "Novel Biologic Countermeasure for Acute Radiation Syndrome" and was set aside for small businesses. Technology Holding has received prior federal contracts...
This is a firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Signablok, Inc., a biopharmaceutical company, for a Small Business Innovation Research (SBIR) Phase I project. The contract is for research and development of a first-in-class TREM-1 radioprotector to prevent the effects of acute radiation syndrome. The project has a total potential value of $220,006.07 and is a set-aside designated for small businesses. Signablok has received previous SBIR grant funding from...
The Department of the Army Medical Command awarded a $549,725 firm fixed price Small Business Innovation Research Program Phase III follow-on medical research and development contract to Synedgen, Inc. for the development of technologies that control scar formation after burn injuries. As the prime contractor, Synedgen will leverage its expertise in regenerative medicine and wound healing to advance scientific knowledge and technologies aimed at reducing scarring and improving outcomes for...
<p>This is a $100,000.00 Small Business Innovation Research (SBIR) Phase I contract awarded by the U.S. Department of Homeland Security (DHS), Countering Weapons of Mass Destruction office, to Polymerplus LLC, a for-profit limited liability company. The contract is a firm fixed-price definitive contract with an ultimate completion date of October 31, 2015. This SBIR Phase I award funds research and development efforts by the small business contractor.</p>
This is a Defense Health Agency (DHA) Small Business Innovation Research (SBIR) Phase II contract, awarded to X-Therma Inc., a minority-owned, small disadvantaged, economically disadvantaged women-owned small business. The contract has a total potential value of $998,967.41 and is a fixed-price level of effort contract. The research and development work will be performed in Vallejo, CA, with a completion date of May 24, 2020. This SBIR Phase II contract is a follow-on to a previous SBIR Phase...
<p>This is a $1,700,320.72 cost-plus-fixed-fee contract awarded by the U.S. Army Contracting Command (ACC) Aberdeen Proving Ground to Exicure, Inc., a small business concern, under the SBIR Phase II program. The contract is for research and development entitled "Genetically Programmable Spherical Nucleic Acids as Rapidly Adaptable Nanotherapeutics" and has a period of performance through January 31, 2016. This SBIR Phase II contract was set aside for small businesses.</p>
The U.S. Defense Health Agency (DHA) awarded a $249,993.28 Small Business Innovation Research (SBIR) Phase I firm-fixed-price purchase order to Glyphic Biotechnologies, Inc., a minority-owned, small disadvantaged business, for the development of anti-glycan antibodies against multi-drug resistant ESKAPE wound pathogens. The contract has a completion date of November 7, 2024 and was awarded on April 8, 2024. Glyphic Biotechnologies is a biotechnology startup focused on developing...